News

Back

Oxford and Novaxia partner for its first French life sciences acquisition

As part of the €1 billion investment plan Oxford acquires Biocitech — a 21,000 square metre life sciences hub.

November 17, 2022

 PARIS

Oxford Properties Group (“Oxford”), a leading global real estate investor, asset manager and business builder, and Novaxia, a premier French urban developer, (“the Partnership”) has completed the acquisition of the Biocitech life sciences campus in Paris, France. The deal marks the first acquisition of the Partnership, announced in May this year, to invest approximately €1 billion to acquire and develop life sciences buildings across France. Biocitech, located in the Romainville submarket of Paris, comprises 21,000 square metres of lab, office and specialist storage space across seven buildings and enjoys a rich history as a life sciences hub. The campus is leased to 17 occupants including Galapagos, Mutabilis and Nextdot. Two-thirds of the occupiers are mature companies with the remaining third start-ups, creating a scientific community with endeavours across biotechnology, biopharmaceuticals, bioinformatics, the provision of scientific and technological services as well as medical devices and equipment. 

 “Building a global life science business of scale represents one our highest conviction investment strategies,” commented Pierre Leocadio, Senior Vice President and Head of European Investment at Oxford Properties. “This acquisition presents us with an exciting opportunity to enter the Paris life sciences market, which is underpinned by high occupier demand yet an acute undersupply of space. At Biocitech, we aim to create a premier campus that serves the entire life and product cycle of biotech firms which is an increasingly important sector in France. “We will use our early mover advantage and leverage our global experience from across North America and the United Kingdom to create compelling life sciences real estate solutions in the French market. We look forward to working with our local partner, Novaxia, on the first project of our partnership to help biotech firms research, develop and then manufacture the life-changing therapeutics of tomorrow.”

 Oxford and Novaxia have plans to substantially invest in and reposition the Biocitech site. The project plans to create close synergies between occupiers and to optimize opportunities for internal and external collaboration. To better serve Biocitech’s occupiers, work will be undertaken in the short term to improve the laboratory space and reduce energy consumption. The Bioctech site combines both income producing properties with future development potential to expand the campus to meet the strong demand in the Paris region for cutting-edge for life sciences facilities while offering new and accessible services for the city.

Joachim Azan, Founding President of Novaxia, commented, "With the acquisition of Biocitech, we are taking a first step in creating places that represent the entire life sciences value chain (research laboratories, incubators, accelerators and production plants). Real estate will thus be the starting point for scientific innovation so that France retains its best researchers, its best companies and strengthens its scientific sovereignty. With Oxford, we are at the beginning of a partnership, which plans to make further acquisitions," explains Joachim Azan, Founding President of Novaxia. 

 

Aude Landy-Berkowitz, Managing Director of Novaxia Development added, "The development of life sciences requires real estate that meets the technical needs and uses of a community. In France there is a shortage of suitable buildings. The requirements are multiple and specific in terms of water, air, height or safety. We will develop real estate that is complementary and synergistic, adaptable with enclosed as well as shared spaces in the service of research and innovation and suitable to small start-ups as well as large companies. With Biocitech, we are creating new campuses open to cities and residents, just like those in Amsterdam, Oxford or Boston.”

With its global experience in life sciences, Oxford Properties will complement Novaxia's local knowledge. Since 2017, Oxford Properties has developed extensive life sciences experience through credit and equity investments as well as the development of laboratories and GMP facilities. Oxford now operates across the top 10 U.S. life sciences markets as well as in London and Cambridge in the UK. The acquisition of Biocitech is in line with Oxford’s objective to invest in the French market and build a market leading global life science business of scale. Novaxia has built up an in-house team of experts in life sciences real estate and will work closely with the Oxford Properties team on a daily basis.